RESCEU (REspiratory Syncytial virus Consortium in EUrope)
The RESCEU project aims to develop robust evidence on respiratory syncytial virus (RSV) disease burden and economic impact in Europe and provide infrastructure to perform future pivotal clinical trials for RSV vaccines and therapeutics.
Summary (Research in a nutshell)
Human respiratory syncytial virus (RSV) is a viral infection which can cause severe respiratory disease in the very young, elderly and in high risk groups such as premature babies or adults with chronic obstructive lung disease.
RESCEU project is an Innovative Medicines Initiative (IMI) funded project under the EU’s Horizon 2020 programme and has been funded for 5 years from 2017 to 2021. It comprises six work packages.
Using a multidisciplinary and international approach, RESCEU brings together clinicians, epidemiologists, scientists, health economists, statisticians, public health professionals, patient organisations, regulatory agencies and industry to address key gaps in knowledge of RSV. The project is timely given the many RSV vaccines and therapeutics currently under development.
Key People
| Name | Role |
|---|---|
| Professor Harish Nair | Professor of Paediatric Infectious Diseases and Global Health, Project Coordinator |
| Professor Harry Campbell | Professor of Genetic Epidemiology and Public Health |
| Rachel Reeves | Research Fellow |
| Ting Shi | Research Fellow |
| Anne Douglas | Research Fellow |
| Stephanie Scott | Research Assistant |
| You Li | PhD student |
| Professor Steve Cunningham | Professor of Paediatric Respiratory Medicine (based in Centre for Inflammation Research) |
| Professor Debby Bogaert | Scottish Senior Clinical Fellow and Honorary Consultant in paediatric infectious diseases (based in Centre for Inflammation Research) |
Contact
Professor Harish Nair: harish.nair@ed.ac.uk
Website
Key publications
No publications yet.
Key Collaborations
ECDC (European Centre for Disease Control)
WHO (World Health Organisation)
GIHSN (Global Influenza Hospitalisation Surveillance Network)
RSV GEN (RSV Global Epidemiology Network)
ReSViNet (Respiratory Syncytial Virus Network)
Partners
University of Antwerp, Belgium
University Medical Centre Utrecht, Netherlands
University of Oxford, UK
Synapse Research Management Partners S.L, Spain
Imperial College of Science, Technology and Medicine, UK
Servicio Galego de Saúde, Spain
Varsinais-Suomen sairaanhoitopiirin kuntayhtymä, Finland
Rijksinstituut voor Volksgezondheid en Milieu (National Institute for Public Health and the Environment), Netherlands
Statens Serum Institut, Denmark
Academisch Ziekenhuis Groningen, Netherlands
Fondazione PENTA, Italy
AstraZeneca AB
Pfizer Limited
GlaxoSmithKline Biologicals SA
Sanofi Pasteur
Janssen Pharmaceutica NV
Novavax Inc.
Funders
Innovative Medicines Initiative 2 Joint Undertaking
European Union’s Horizon 2020 research and innovation programme and EFPIA (Grant no. 1156019)
Timeline
January 2017- December 2021
Scientific themes
Respiratory Syncytial Virus, respiratory infections, epidemiology, burden of disease, clinical trials
Methodology keywords
Systematic review, clinical trial, biobank, record-linkage, epidemiology, health economics, modelling